Physician profile
Daniel Sanchez
NPI 1508278532
$1,214.98
in general payments reported to CMS, 2019-2025
14 companies · $180 in 2025
The $180 reported for 2025 was more than what 78% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2021: $13.74 · 2022: $62.59 · 2023: $446 · 2024: $386 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $853 · Education: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $853.03 |
| Education | $157.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $343.69 | 2024-2025 | Enhertu |
| Incyte Corporation | $235.65 | 2022-2023 | Jakafi |
| Merck Sharp & Dohme LLC | $156.06 | 2022-2024 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $150.29 | 2023-2025 | |
| Genentech USA, INC. | $116.47 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.75 | 2024-2025 | Alunbrig, Iclusig |
| Adaptive Biotechnologies Corporation | $43.40 | 2023 | Clonoseq |
| Janssen Biotech, INC. | $24.65 | 2022 | |
| Sobi, INC | $20.64 | 2023 | |
| Werfen USA LLC | $20.50 | 2025 | |
| Eisai INC. | $17.51 | 2023 | |
| Stemline Therapeutics INC. | $14.46 | 2024 | Orserdu |
| Astrazeneca Pharmaceuticals Lp | $13.74 | 2021 | |
| Integra Lifesciences Corporation | $11.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.